- Home
- FSHP vs ACOG Comparison
FSHP vs ACOG Comparison
Compare FSHP & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- ACOG
- Stock Information
- Founded
- FSHP 2018
- ACOG 2000
- Country
- FSHP United States
- ACOG Canada
- Employees
- FSHP N/A
- ACOG N/A
- Industry
- FSHP
- ACOG
- Sector
- FSHP
- ACOG
- Exchange
- FSHP NYSE
- ACOG Nasdaq
- Market Cap
- FSHP 92.6M
- ACOG 80.3M
- IPO Year
- FSHP 2024
- ACOG N/A
- Fundamental
- Price
- FSHP $10.45
- ACOG $10.80
- Analyst Decision
- FSHP
- ACOG Strong Buy
- Analyst Count
- FSHP 0
- ACOG 1
- Target Price
- FSHP N/A
- ACOG $20.00
- AVG Volume (30 Days)
- FSHP 744.0
- ACOG 67.2K
- Earning Date
- FSHP 01-01-0001
- ACOG 08-14-2025
- Dividend Yield
- FSHP N/A
- ACOG N/A
- EPS Growth
- FSHP N/A
- ACOG N/A
- EPS
- FSHP 0.21
- ACOG N/A
- Revenue
- FSHP N/A
- ACOG $2,928,654.00
- Revenue This Year
- FSHP N/A
- ACOG N/A
- Revenue Next Year
- FSHP N/A
- ACOG N/A
- P/E Ratio
- FSHP $49.13
- ACOG N/A
- Revenue Growth
- FSHP N/A
- ACOG N/A
- 52 Week Low
- FSHP $9.99
- ACOG $3.75
- 52 Week High
- FSHP $10.48
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- ACOG N/A
- Support Level
- FSHP N/A
- ACOG N/A
- Resistance Level
- FSHP N/A
- ACOG N/A
- Average True Range (ATR)
- FSHP 0.00
- ACOG 0.00
- MACD
- FSHP 0.00
- ACOG 0.00
- Stochastic Oscillator
- FSHP 0.00
- ACOG 0.00
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.